SEC Form 3 · accession 0001706399-26-000002

ADARx Pharmaceuticals, Inc. · ADRX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Erez Chimovits

Director

Period of report

Sep 24, 2026

Accepted (ET)

Sep 24, 2026 · 6:38 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001802369

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Preferred Stock^F2,F3,F1	—	holding	—	—	—	—	—	Common Stock	7,127,019	—	I
Series B Preferred Stock^F2,F3,F1	—	holding	—	—	—	—	—	Common Stock	1,333,975	—	I
Series B-1 Preferred Stock^F2,F3,F1	—	holding	—	—	—	—	—	Common Stock	513,067	—	I
Series C Preferred Stock^F2,F3,F1	—	holding	—	—	—	—	—	Common Stock	256,448	—	I

Explanation of responses

F1Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") will automatically convert on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date.
F2These securities are held directly by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("Israel GP") is the general partner of OIP II. OrbiMed Advisors Israel II Limited ("Advisors Israel") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to have voting power and investment power over the securities held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and the Reporting Person, each of whom disclaims beneficial ownership of the shares held by OIP II.
F3Each of the Reporting Person, Israel GP, and Advisors Israel disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.